(firstQuint)An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis.

 Subjects who took part in GWMS0001 Part A were invited to continue to receive GW-1000-02 in this four-week open-label part of the study.

 Subjects received open-label cannabinoid extract (GW-1000-02) for four weeks, either with or without peppermint flavouring, according to their study centre.

 Subjects who completed the study could choose to continue receiving GW-1000-02 by entering the long-term safety extension follow-on study.

.

 An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis@highlight

An open-label extension study in which patients with multiple sclerosis received GW-1000-02 [named Sativex(R) in Canada and also named Sativex(R) Oromucosal Spray] for four weeks in an open-label manner.

